Praxis Biologics vaccine grants
Executive Summary
Two $50,000 Phase I Small Business Innovation Research grants received by firm. The first, from the Natl. Institute of Allergies & Infectious Diseases, covers development of a new infant Haemophilus influenzae bacterial (HIB) vaccine. Praxis already markets a Hib conjugate vaccine, B-CAPSA-I, and has completed Phase II study for a successor compound. The second grant, from the U.S. Department of Agriculture, is for research on a vaccine for Salmonella and other infections in poultry.
Two $50,000 Phase I Small Business Innovation Research grants
received by firm. The first, from the Natl. Institute of Allergies
& Infectious Diseases, covers development of a new infant
Haemophilus influenzae bacterial (HIB) vaccine. Praxis
already markets a Hib conjugate vaccine, B-CAPSA-I, and has
completed Phase II study for a successor compound. The
second grant, from the U.S. Department of Agriculture, is for
research on a vaccine for Salmonella and other infections in
poultry. |